DOCSLIB.ORG

L 1996 AUTHOR Indexaalavi, Author Index €¢1996 2101

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
L 1996 AUTHOR Indexaalavi, Author Index €¢1996 2101 lINDEXAalavi, 1996 AUTHOR 286P(ab)Aaron,A, 231P(ab)Akbunar, 3P(ab)Amanullah,M, 102P(ab)Atkins,H, 1023,1578,JR, 513, 676Aaron,AD, 1 289P(ab)Akerman,AT, 69P(ab),93P(ab),A, 72P(ab)Atkins,HL, 239, (ed).281P(ab)Baltimore,1591(ed), 1591 276P(ab)Abdel-Dayem,LA, 76P(ab)Akhtar,KK, 181P(ab),182P(ab)Amarenco, 209P(ab)Atsumi,MS, 1662,242P(ab),HM, 993Akhurst,M, 181P(ab)Attle,H, 24P(ab)Balza.D, 251P(ab),277P(ab), 131P(ab),132P(ab)Akinci,T, 1683, 1976Amato, P, 242P(ab)Aubert,JN, 238P(ab)Bandy,E, 301P(ab)Abdel-Nabi, 32P(ab)Ambrose,R, 1860Aubrey,B, 224P(ab)Bangard,D, 9P(ab),135P(ab),H, 289P(ab)Akisik,H, 6P(ab),193P(ab),KR, 174P(ab)Augustine,BA, 100P(ab),265P(ab)Bangerter.M, 136P(ab),238P(ab), 242P(ab),251P(ab),M, 202P(ab)Amdur, 90P(ab)Auinger,SC, 13S, 259P(ab)Abe, 277P(ab),301P(ab)Akizawa, 285P(ab)Amerenco,R, 241P(ab)Aung,Ch, 262P(ab)Banish.M, 1444Abe,H, 1976Amin, G, 174P(ab)Aureli,MT, I24P(ab)Banks,MR. 294P(ab)Abe,R, 7P(ab)Aktay,H, 993Amyotte,TM, 1883Aurengo,M, 1872, 1876. 146Bannerman,D, 955Abe,S, 1815Akyuz,R, 237P(ab)Anayat,G, 1773Austin-Lane,A, 847, 1578Banshai, J, 320Abella-Columna,Y, 139P(ab)Al-Bunny,C, 147P(ab)Anazawa,AR, 284P(ab)Avedon,JL, 150P(ab)Baquey,S. E,lllP(ab), 289P(ab)Al-Hallaq,A, 1460Anderson,Y, 46Avril, M, 863Bar, C, 132P(ab),136P(ab), 212P(ab)Al-Mohannadi,H, 805Anderson,BG, 99P(ab)Awata,N, 1815Bar-Sever,RS, 139P(ab)Abi-Dargham, 289P(ab)Al-Nabulsi,S, ab).71P(ab),CJ, 1294, 61 P( 410Awotwi-Pratt,S, 22P(ab),28P(ab),Z, 81, 33P(ab),285P(ab)Abitbol,A, 87P(ab)Al-Samrrai,I, 95P(ab),128P(ab), l48P(ab)Ayyangar,J, 292P(ab)Bar-Shalom, 121P(ab)Al-Za'abi,E, 201P(ab),302P(ab)Anderson, 90P(ab)Aziz,KM, 139P(ab)Baran,R, 23P(ab)Abraham,C, 289P(ab)Alaamer.AS,K, 277P(ab)Azizi,M, 242P(ab), 230P(ab)Baranowska-Kortylewicz,Y. 161P(ab)Abramovici,SA, 1832Alam, 1058, 107P(ab)Anderson,JH, 68P(ab)Azuma,N, J,315, 2017Abrams, J, 646Alarcon,MS, 227P(ab)Anderson,JR, 244P(ab)Baars,M, 150P(ab),13S,90P(ab). 1589Abrams,DN, 276P(ab)Alauddin,GS, 1336Andersson,PJ, 1331, 22SBarbaras,16S, 19S, 843Aburano,MJ, 107P(ab),193P(ab)Alavi,MM, 1519,2002Ando,P, 584Baas,JB, 172P(ab)Barbaries,LG, 44P(ab),291P(ab),T, 5P(ab), 781André-Fouet,H, 584Babain,P, 118P(ab)Barber,E, 292P(ab)Acampa, 92P(ab),114P(ab),A, 723, 147P(ab)Andreaco,X, 296P(ab)Babchyck,R, 53P(ab),301P(ab)Barbet,HB, 138P(ab),156P(ab),W, 117P(ab),130P(ab), 85P(ab),86P(ab)Andreas.J,M, 1760Babich,B, 159P(ab)Achong, 132P(ab),148P(ab), 33P(ab),I43P(ab),JW, 4P(ab), l29P(ab)Barclay,J, 1853, 267Achong,D, 165P(ab),176P(ab), 104P(ab)Andrews, 152P(ab),228P(ab), 1891Barclay,AB, 113P(ab),240P(ab)Ackerman,DM, 246P(ab),252P(ab), 157P(ab),260P(ab)Andrich,D, 239P(ab),240P(ab), 315Bardet,PD, 265P(ab),276P(ab), 269P(ab)Bacharach, 1853Bardies,S, 857Ackermann,C, 278P(ab),283P(ab), 34P(ab),253P(ab)Anesi,MP, 1731, 786,1557, SL, 690, 1853Bareille,M, 78P(ab),215P(ab)Adachi,RJ, 284P(ab),295P(ab), 25P(ab),39P(ab),1795, 863Bareket,R, 17N(7)Alazraki, 185P(ab)Angelberger,E, 93P(ab),99P(ab),60P(ab), 182P(ab)Barendswaard,Y, 263P(ab),296P(ab)Adam,I, 48P(ab),84P(ab),NP, 1575, 1931,5P(ab), P, 1480, 160P(ab),161P(ab), 1052Bares, E, 125P(ab),179P(ab), 251P(ab)Angeletti,20P(ab), 211P(ab),253P(ab)Bachen, l34P(ab),137P(ab),R, 27P(ab), P(ab)Adam,L-E, 221 293P(ab),307P(ab)Alberto, 1452Anjilvel,S, 140P(ab)Barker, 2024Adam,LE, 123P(ab)Annibale,S, 257P(ab),264P(ab),P, IP(ab)Barker,C, 21 36P(ab)Adamietz,M, 165P(ab)Alberts,R, 1452Anthony,B, 296P(ab)Bachmann, 157P(ab)Barker,FG II, 1942Adams,IA, 276P(ab)Albertson,KR, 270P(ab)Antonini,DC, 218P(ab)Badawi,R, 1795Barlow,WC, 1001Adams,BK, 1535AlbertusPiers,DA, 281P(ab)Aoyama,A, 73P(ab)Bading.JR,RD, 92P(ab)Barnes,R, 80P(ab)Adams,KF, 482Albin, C, 179P(ab)Appel,T, 107P(ab),155P(ab)Baetens, 81Barnes,PD, 121P(ab),137P(ab)Adelson,S, 164P(ab)Albright,RL, 265P(ab)Appelbaums,M, 275P(ab)Baro,WE, 263P(ab)Alderson,RE, 233P(ab)Aprile,FR, 91P(ab)Bag,J. 16Baron,ME, 269P(ab)Adelstein,PD, 5P(ab)Aleksandrova,PO, 185P(ab)Arai,C, 1662Bagheri,R, 95Baroni,J, 343,102P(ab),SJ, 315, IP(ab)Alexander,Y, 5 64P(ab),254P(ab)Araikum,T, 1819, 14P(ab),149P(ab)Bagnara,B, 238P(ab)Barre,S, 187P(ab),229P(ab), 158P(ab)Alexander,E, 95Barrett,L, 19S,ISAdiseshan,IOS, 16S, 1690Alexander,HR, 1323Araki.T,S, 243P(ab)Bahadur,MC, 53P(ab),63P(ab),HH, 276P(ab)Alexoff,RW, 1819,64P(ab),1551, 137P(ab)Bahr,S, 124P(ab),301P(ab)Barrett, 79P(ab)Adler,P, 1 P(ab)Alfano,D, 41 254P(ab)Araño, 1846Bahtiarian,A, 302P(ab)Adler,B, 260P(ab)Algozine,B, 7P(ab)Aras,Y, 22P(ab),74P(ab)BaidjnathEA, 117P(ab),H9P(ab),JA, 99P(ab)Affleck,LP, 1575,47P(ab),CA, 177P(ab),257P(ab),T, 1662, 129P(ab),151P(ab), 191P(ab)Afriyie,DJ, 84P(ab)Ali, 291P(ab)Araujo, 972Baidoo,Panday, RKL, 202P(ab),232P(ab)Barrington, 103P(ab),242P(ab)Agis,MO, 1356Alisauskus,SA, 926, 92P(ab),148P(ab),LI, 723, 189P(ab)Bailer,KE, 96P(ab)Alkan,R, 176P(ab)Arbab.AS, 115P(ab)Bailey,H, 87P(ab),282P(ab)Barrington,S, 5P(ab)Agnew,H, 184P(ab)Allada,M, 1819,64P(ab),1551, 873Bailey,AG, 104P(ab)Agresti,JE, 1717Allen,V, 254P(ab)Arbizu, 85P(ab),148P(ab),DL, 1771Barrio, SF, P(ab)Ahlberg,R, 251 HOP(ab),269P(ab),M, 93P(ab)Areeda,J, 271P(ab)Bailey, 79P(ab),107P(ab),JR. 37P(ab),58P(ab),AW, 301P(ab)Allen-Mersh, 81P(ab)Arildsen,J, 19SBair,NO, 147P(ab),l93P(ab)Barran, 150P(ab),177P(ab)Ahlman, 54P(ab)Almeida,T, 131P(ab)Arimizu,RC, 829Baje,HJ, 217P(ab)Aloj,P, 258P(ab),277P(ab)Arisaka,N, 622Baker,M, 162P(ab),272P(ab),B, 1519,2002Ahlstrom,H, 99P(ab),118P(ab),L, 1408, 198P(ab)Bakheet,RJ, 84P(ab), 292P(ab)Barrow, 1766Ahmad,H, 32, 199P(ab),203P(ab), 184P(ab)Aronochick,H, 26Bakheet,S, 198P(ab)Barsa,J,SA, 843, 69P(ab)Ahmad,A, 204P(ab),254P(ab)Alonso, 117P(ab)Aronsson,JM, 993Bakkaloglu,SM, 301P(ab)Bartell,251P(ab), 457Ahmed,K, 1519Arrighi,EF, 145P(ab)Bakker,A, 159P(ab)Bartenstein.KM, 993Ahn, M, 1919(le),266P(ab)Alper,O, 282P(ab)Arthur,JA, 67P(ab)Bakker,M, 22P(ab),157P(ab),P, 1 268P(ab)Ahn,BC, 258P(ab)Asenbaum,JE, 1388,190P(ab)Bal,WH, 108, 278P(ab)Barth, 252P(ab)Ahonen,SH, 289P(ab)Alpen,E, 159P(ab), 1931Ashburner,S, 218P(ab)Banlett,I, 22P(ab)Aicher,A, 33P(ab),125P(ab),NM, 950, 271P(ab)Ashby,J, 137P(ab)Baldassarri,CS, 39P(ab),93P(ab)Bartolic,ML, 1795, 463Aigbirhio,KP, 161P(ab),239P(ab), 203P(ab)Ashihara,CR Jr., 16SBaldwin, S, 141P(ab)Aigner,FI, 244P(ab)Aiston, 781Ashook,T, 2006Baldwin,D, 259P(ab)Bass,E, 1524Aioi,R, 191P(ab)Altieri,KL, 46Atahan,G, 11.32P(ab),33P(ab),RM, 61P(ab),128P(ab),LA, 51P(ab), H6P(ab)Aizawa,S, 565Altmann,P, 1956Atasever,L, 44P(ab),272P(ab), 201P(ab)Bassa, 12P(ab)Ajami,Y, 234P(ab),235P(ab)Alvarez,A, 139P(ab)Atay,T, 285P(ab)Balfore, 1472,261P(ab)Bassett,P, 931, 255P(ab)Akabani,K, 233Atkins,S, 254P(ab)Balkanci,J, G, 89P(ab),90P(ab), RD, 1491Amano, FB, 643, 1639Atkins, F, 291P(ab)Ballinger, LW, 269P(ab) Author Index •1996 2101 Bassingthwaighte, JB, Benali, H, 217P(ab) Berthele, A, 278P(ab) Blumenthal, RD, 96P(ab), 106P(ab) 106P(ab), HOP(ab), Benard, F, 130P(ab) Berthold, T, 441, 121P(ab) 102P(ab), 168P(ab), Bouchard, M, 723 146P(ab) Benari, B, 93P(ab), 180P(ab) Bertrand-Caix, J, 863 169P(ab) Boudreau, RJ, 142P(ab), Bastidas, D, 673, 1016, Benazzouz, F, 189P(ab) Besnard, J-C, 186P(ab) Blundell, P, 17P(ab) 189P(ab) 38P(ab), 152P(ab) Bencherif, B, 7P(ab)0 Best, S, 44P(ab), 272P(ab) Boazi, M, 186P(ab) Bourguignon, M, 217P(ab) Baudin, E, 912, 1830, Bender, H, 1496, 100P(ab), Better, N, 1618 Bobba, K, 47P(ab) Bourque, JP, 1031 20P(ab) 134P(ab), 138P(ab), Bettman, L, 103P(ab) Bobigny, CHU, 274P(ab) Bousser, MG, 1976 Bauer, B, 76P(ab) 236P(ab), 252P(ab), Beutler, JJ, 289P(ab) Bock, E, 248P(ab) Bouville, AC, 24N(12) Baum, H, 107P(ab) 265P(ab) Beyer, GJ, 51P(ab) Bock, F, 241P(ab) Bowen, WD, 7P(ab), Baum, JK, 74P(ab) Bendriem, B, 5, 118, 1557, Beyer, J, 104P(ab), 159P(ab) Bock, M, 296P(ab) 205P(ab), 267P(ab) Baum, RP, 362, 1942, 76P(ab), 154P(ab), Bhargava, K, 199P(ab), Bockisch, A, 103P(ab), Boxen, I, 1578 9P(ab), 121P(ab), 137P(ab) 170P(ab), 217P(ab), 244P(ab) 104P(ab), 144P(ab), Boy, C, 113P(ab) Baum, S, 854 226P(ab) Bhattathiry, MM, 306P(ab) 159P(ab), 209P(ab), Boyd, J, 136P(ab), 264P(ab) Baumeister, R, 25P(ab) Benjamin, C, 75P(ab) Bhatti, MA, 114P(ab) 233P(ab) Boyd, SJ, 744 Bausart, R, 258P(ab) Benkelfat, C, 113P(ab), Bhulya, T, 242P(ab) Bode, A, 154P(ab) Boz.A, 1916(le), 1917(le) Bautovich, G, 90P(ab) 284P(ab) Bi, Z, 197P(ab) Boden, JA, 868 Braams, JW, 897 Bavisotto, L, 140P(ab) Bennett, A, 1749 Bianchi, V, 13P(ab) Bodi, I, 287P(ab) Bracco, L, 278P(ab) Bax, JJ, 1631,59P(ab), Bennett, JA, 87P(ab), Biassoni, P, 243P(ab) Boer, GJ, 134P(ab) Brachman, M, 46 60P(ab), 176P(ab), 148P(ab) Biegon, A, 40P(ab) Boerman, OC, 1392, Bradley, LA, 276P(ab) 178P(ab), 184P(ab) Bennett, LR, 306P(ab) Bien, S, 463 169P(ab) Brady, F, 191P(ab) Bazzicalupo, L, 260P(ab) Bense, S, 99P(ab) Bier, D, 55P(ab) Boersma, LJ, 584 Brady, J, 289P(ab) Beanlands, RS, 174P(ab) Benti, R, 37P(ab), 230P(ab) Bierman, H, 46 Bogdanov, AA Jr., 198P(ab) Brady, LW, 65P(ab), Beattie, B, 53P(ab), 54P(ab) Benlourkia, M, 2040, 2046 Biersack, H-J, lOOP(ab), Bogers, AJJC, 748 265P(ab) Beauduin, M, 258P(ab) Benz, P, 209P(ab) 134P(ab), 138P(ab), Boggs, R, 226P(ab) Brady, M, 138P(ab) Beaumier, P, 144P(ab) Beppu, Y, 1444 236P(ab), 243P(ab), Bohuslavizki, KH, 4P(ab), Brady, TJ, 198P(ab) Bebe, M, 29P(ab) Bera, R, 249P(ab) 252P(ab), 265P(ab), 142P(ab), 246P(ab), Brancate, R, 967 Becherer, A, 1480, 254P(ab) Berardino, S, 13P(ab) 273P(ab), 280P(ab) 256P(ab), 257P(ab) Brandau, W, 1865, 1990, Beck, D, 225P(ab) Berdichevsky, D, 125P(ab) Biersack, HJ, 626, 1496, Boissier, B, 233P(ab) 49P(ab), 268P(ab) Becker, DV, 24N(I2) Berenl, S, 201, 163P(ab), 1962 Bok, B, 35P(ab), 101P(ab), Brandt, A, 142P(ab) Becker, J, 27P(ab), 200P(ab) 164P(ab) Bieszk, JA, 149P(ab) 113P(ab), 2l7P(ab), Brandt, T, 122P(ab) Becker, W, 362, 255P(ab) Berg, G, 1519 Bigio, E.
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • Development of Analytical Methods Based on Near Infrared
    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Development of analytical methods based on Near Infrared Spectroscopy for monitoring of pharmaceutical and biotechnological processes and control of new psychoactive substances Aira Yira Miró Vera Doctoral Thesis PhD Program in Chemistry Professor Manel Alcalà Bernàrdez, PhD, Director Department of Chemistry Faculty of Sciences 2019 Acknowlegments This research was funded by MINECO (Spain) through the project CTQ 2016-79696-P (AEI/FEDER, EU). I appreciate the academic support of Professor Manel Alcalà Bernàrdez. I am also grateful to Professor Francisco Valero and personnel of the Department of Chemical Engineering UAB, Professor Sergi Armenta and personnel of the Department of Analytical Chemistry University of Valencia for the kind provision of samples, instruments, as well as their valuable collaborative efforts. 2 ABSTRACT The Near Infrared Spectroscopy (NIRS) is an analytical technique based on the interaction of electromagnetic radiation in the wavelength range 780-2500 nm and matter. The NIR spectrum can be considered as a “fingerprint” of each chemical compound or mixture of them, which contains absorption bands that are the result of overtones and combinations of the fundamental vibrations observed in the Mid-Infrared region.
    [Show full text]
  • List of SSRI Effects Spirits for MD Widespread Use of Antidepressants
    List of SSRI Effects Spirits for MD widespread use of antidepressants in new SSRI-era, 2C family, 5-HT2Ay overactivity, 5-HT pro-drugs, abdominal distension, abnormal brain states, Abnormal Dreams, abnormal personalities, Abnormal Thinking, abnormally extreme emotions, abrupt cessation, abrupt interruption therapy, Acting aggressive, acting on dangerous impulses, active metabolite, acute pharma- cological action of meds, adaptation phase, & theory, addictions, Adhyperforin, adverse drug reaction, adverse effects, Advil, affect newborns, affect reuptake inhibition of serotonin & norepinephrine, aggression, aggressiveness, agitation, agomelatine, agoraphobia, akathisia, Alaproclate, alcohol use, alcohol Abuse, alcohol mixed with meds, alcoholism, Aleve, Allosteric serotonin reuptake inhibitor, alprazolam, altering hormones, alteration of neuronal activity in central nervous system, altered brain, altered mind, altered thinking, ambien, Amitifadine, amitriptyline, Amnesia, Amoxapine, Anafranil, analgesic, anorexia nervosa, anorgasmia, anti- depressant withdrawal aids, Anti-inflammatory, antiarrhythmic agents, antidepressant activity, Antidepressant Nightmares, antidepressant withdrawal symptoms, antidepressant-associated mania, antidepressant- associated psychosis, antidepressants, antipsychotic diphenylbutylpiperidine derivative, anxiety, anxiety related disorders, appetite changes, Aropax, arson, Asentra, Aspirin, ASA, Attempted Murder, Attempted suicide, auditory hallucinations, autism, autoimmune hypersensitivity, autonomic dysfunctions,
    [Show full text]
  • New Psychoactive Substances in Australia
    NEW PSYCHOACTIVE SUBSTANCES IN AUSTRALIA Rachel Sutherland BSocSc (Hons, Criminology) A thesis in fulfilment of the requirements for the degree of Doctor of Philosophy National Drug and Alcohol Research Centre School of Public Health and Community Medicine Faculty of Medicine University of New South Wales November 2018 i THESIS/DISSERTATION SHEET Surname/Family Name Sutherland Given Name/s Rachel Anne Abbreviation for degree as give in the University calendar PhD Faculty Medicine School School of Public Health and Community Medicine Thesis Title New psychoactive substances in Australia Abstract 350 words maximum: (PLEASE TYPE) Over the past decade, countries worldwide have observed the rapid emergence of substances collectively referred to as ‘new psychoactive substances’ (NPS). To date, hundreds of NPS have been identified; however, for the most part very little is known about these substances. The exponential growth of NPS, combined with uncertainty regarding potential harms, has generated considerable concern amongst policy makers and there is international consensus regarding the need for ongoing monitoring and research into the NPS market. However, much of the research conducted in this area originates from Europe and the United States, with Australian-specific studies relatively scarce. This thesis aimed to address this gap in Australian specific studies using two data sources: the 2013 National Drug Strategy Household Survey (NDSHS: a general population prevalence survey) and the Ecstasy and related Drugs Reporting System (EDRS: a national survey of high frequency psychostimulant consumers). Specifically, this thesis aimed to: 1) determine if there was a distinct group of exclusive Australian NPS consumers; 2) examine rates of use of different classes of NPS amongst people who use other illicit substances; 3) examine the motivations associated with NPS use; and 4) explore the purchasing and supply patterns of NPS consumers.
    [Show full text]
  • 伊域化學藥業（香港）有限公司 Bicyclooctanes
    ® 伊 域 化 學（香 藥 香 港） 業 港有 有 限 限 公 公 司 司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICKYICK----VICVICVICVIC 伊域伊域伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com Bicyclooctanes Product Code CAS Product Name CC-0052BA 39746-00-4 (-)-COREY LACTONE BENZOATE PH-0500B 423165-07-5 (1R,3S,5S)-3-(3-ISOPROPYL-5-METHYL-4H-1,2,4-TRIAZOL-4-YL)-8-AZABICYCLO[3.2.1]OCTANE UNIE-14733 162490-88-2 (1S,3R,5R,7S)-1-ETHYL-3,5,7-TRIMETHYL-2,8-DIOXABICYCLO[3.2.1]OCTANE MIS-11307 68313-81-5 (2R,6R,7R)-3-METHYLENE-7-[(4-METHYLBENZOYL)AMINO]-8-OXO-5-OXA-1-AZABICYCLO[4.2.0]OCTANE-2-CARBOXYLIC ACID DIPHENYLMETHYL ESTER MIS-3966 76272-35-0 (3-ENDO)-8-(PHENYLMETHYL)-8-AZABICYCLO[3.2.1]OCTAN-3-AMINE SPI-0830MA 423165-13-3 (3-EXO)-3-[3-METHYL-5-(1-METHYLETHYL)-4H-1,2,4-TRIAZOL-4-YL]-8-(PHENYLMETHYL)-8-AZABICYCLO[3.2.1]OCTANE SPI-2029AE 25333-42-0 (R)-(-)-3-QUINUCLIDINOL UNIE-15428 201660-37-9 (R)-(-)-3-QUINUCLIDINYL CHLOROFORMATE SPI-2029CA 119904-90-4 (S)-(-)-3-AMINOQUINUCLIDINE DIHYDROCHLORIDE MIS-2324 376348-70-8 (S)-3-[3-(3-ISOPROPYL-5-METHYL-[1,2,4]TRIAZOL-4-YL)-8-AZA-BICYCLO[3.2.1]OCT-8-YL]-1-PHENYL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER UNIE-15496 135729-78-1 (S)-N-(1-AZABICYCLO[2.2.2]OCT-3-YL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDE SPI-2378DD 1-(3-AZABICYCLO[3.3.0]OCT-3-YL)-3-(O-TOLYLSULPHONYL)UREA CC-0511GE 140681-55-6 1-CHLORO-4-FLUORO-1,4-DIAZONIABICYCLO[2.2.2]OCTANE BIS(TETRAFLUOROBORATE) SPI-2029EA 5832-55-3 2-(HYDROXYMETHYL)-3,3-QUINUCLIDINEDIOL HYDROCHLORIDE Copyright © 2014 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD.
    [Show full text]
  • Chemical Targeting of Voltage Sensitive Dyes to Specific Cells and Molecules in the Brain
    Chemical targeting of voltage sensitive dyes to specific cells and molecules in the brain Tomas Fiala1,||, Jihang Wang1,||, Matthew Dunn1, Peter Šebej1,12, Se Joon Choi3, Ekeoma C. Nwadibia1, Eva Fialova1, Diana M. Martinez,4 Claire E. Cheetham7, Keri J. Fogle8,9, Michael J. Palladino8,9 , Zachary Freyberg10,11, David Sulzer3,4,5,6* and Dalibor Sames1,2* 1Department of Chemistry, Columbia University, New York, NY, USA. 2NeuroTechnology Center at Columbia University, New York, NY, USA 3Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA. 4Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA. 5Department of Pharmacology, Columbia University Irving Medical Center, New York, NY, USA. 6Department of Molecular Therapeutics, New York Psychiatric Institute, New York, NY, USA. 7Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA, USA. 8Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. 9Pittsburgh Institute of Neurodegenerative Diseases (PIND), University of Pittsburgh, Pittsburgh, PA, USA. 10Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. 11Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA. 12Current address: RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. *Correspondence should be addressed to D. Sames ([email protected]) or D. Sulzer ([email protected]). 1 Graphical abstract: 2 Abstract Voltage sensitive fluorescent dyes (VSDs) are important tools for probing signal transduction in neurons and other excitable cells. These sensors, rendered highly lipophilic to anchor the conjugated -wire molecular framework in the membrane, offer several favorable functional parameters including fast response kinetics and high sensitivity to membrane potential changes. The impact of VSDs has, however, been limited due to the lack of cell-specific targeting methods in brain tissue or living animals.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,084.825 B2 Montefeltro Et Al
    USOO9084825B2 (12) United States Patent (10) Patent No.: US 9,084.825 B2 Montefeltro et al. (45) Date of Patent: Jul. 21, 2015 (54) COMPOSITIONS AND METHODS FOR THE FOREIGN PATENT DOCUMENTS TREATMENT OF PARKINSON DISEASE BY WO WO 88,09810 A1 12, 1988 THE SELECTIVE DELVERY OF WO WO 89,10134 A1 11, 1989 OLGONUCLEOTDE MOLECULESTO WO WO 97.2627O A2 7/1997 SPECIFIC NEURON TYPES WO WO 2007/050789 * 5/2007 WO WO 2007/107789 A2 9, 2007 WO WO 2009,079.399 A2 6, 2009 (71) Applicant: nife Therapeutics, S.L., Armilla, WO WO 2009,079790 A1 T 2009 Granada (ES) WO WO 2011/087804 A2 T 2011 WO WO 2011, 131693 * 10/2011 (72) Inventors: Andrés Pablo Montefeltro, Barcelona WO WO 2011, 131693 A2 10/2011 (ES); Gabriel Alvarado Urbina, WO WO 2012/027713 A2 3, 2012 Nepean (CA); Analia Bortolozzi OTHER PUBLICATIONS Biassoni, Barcelona (ES); Francesc Wersinger et al (FASEB J., vol. 17, pp. 2151-2153 (2003)).* Artigas Pérez, Barcelona (ES); Miquel Wersinger etal (Neuroscience Lett., vol. 340, pp. 189-192 (2003)).* Vila Bover, Barcelona (ES); Maria del Negus etal (J. Pharmacol. & Exp. Therapeutics, vol. 291 No. 1, pp. Carmen Carmona Orozco, Terrassa 60-69 (1999)).* (ES) Gardner et al (Neuropharm. vol. 51, pp. 993-1003 (2006)).* Silva et al (Organic Lett., vol. 9, No. 8, pp. 1433-1436 (2007)).* (73) Assignee: n life Therapeutics, S.L., Granada (ES) Altschul., S.F., et al., “Basic Local Alignment Search Tool.” J. Mol. Biol. 2 15:403-410, Academic Press Limited, England (1990). Beaucage S.L. and Iyer, R.P.
    [Show full text]
  • Rti-11 Ii- Rti-29 Iii- Rti-31 Iv- Rti-32 V- Rti-83 Vi- Rti-298 Vii- Rti-430 Viii- Rti-436 Ix- Win 35,428
    Health Canada Santé Canada STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S) Substance: I- RTI-11 II- RTI-29 III- RTI-31 IV- RTI-32 V- RTI-83 VI- RTI-298 VII- RTI-430 VIII- RTI-436 IX- WIN 35,428 Based on the current information available to the Office of Controlled Substances, it appears that the above substance is: Controlled ☐ Not Controlled X under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s): The substances are analogues of cocaine and are not included under item 2 of Schedule I to the CDSA. Prepared by: _______________________________________ Date: _______________ Vincent Marleau Verified by: _______________________________________ Date: ________________ Manager, NCED, OCS Approved by: _______________________________________ Date: ________________ DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES This status was requested by: Member of Public 2 Drug Status Report Drug: I- RTI-11 II- RTI-29 III- RTI-31 IV- RTI-32 V- RTI-83 VI- RTI-298 VII- RTI-430 VIII- RTI-436 IX- WIN 35,428 (See Table 1 for chemical information). Pharmacological class / Application: Cocaine analogues International status: US: The substances are not listed specifically in the Schedules to the US Controlled Substances Act and are not mentioned anywhere on the DEA website. United Nations: The substances are not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control. Canadian Status: RTI-11, RTI-29, RTI-31, RTI-32, RTI-83, RTI-298, RTI-430, RTI-436, and WIN 35,428 are not listed in the Schedules to the CDSA.
    [Show full text]
  • Rti-111 Nachnahme Rti-111 Nachnahme * Students Get Their Own Ideas on the Perfect
    Rti-111 Nachnahme Rti-111 nachnahme * Students get their own ideas on the perfect. about 3x12 evaporator for sale Mamanar kama pothai kathai Urut b2b pudu Rti-111 nachnahme Menu - Modifikasi atx menjadi charger aki Amoi b2b setapak Friends links Hk psg1 sniper rifle for sale, Mini militia 4x speed, Ww spbo livescore Rti-111 nachnahme. Original RTI-111 (Dichloropane) IUPAC name: Methyl com, Ladbrokes odds on irish lotto (1R,2S,3S,5S)-3- (3,4. Nachname - Alternativ könnt ihr ein Kommentar bei der Bestellung hinterlassen,. Kaufen Research Chemicals Deutschland. bloggers Kahoot cheat engine Vertrauenswürdige Research Chemical shop. Kaufen 2-MMC, 3-MEC, 4- Asal pemilik po bus sinar jaya CMC, a-PVT, AB-CHMINACA. Nachnahme Buy. EU Research Chemical Shop with COD/ Nachnahme , Buy here Wholesale research chemicals like A-PVP, MDPHP, 3-MMC, 4-CL-PVP, 4-CMC , TH-PVP, MDPHP Wholesale Research. 11 rijen · Easy payment via Bitcoin, Bank transfers & Nachname / Cash on Delivery . EU based vendor. YOU CAN BE SURE this is the real RTI-111 ( Dichloropane), RTI-111 / Dichloropane – Kokain Analog & Research Chemical (Substanzinfo) RTI-111 (aka Dichloropane / Dichloropan / O-401) ist ein Upper, der zu den Phenyltropanen. RTI-111 or Dichloropane is the perfekt stimulant, very clear. the delivery from EU to Germany is very gut. the service is ok and Dennis is a nice guy. Jetzt in unserem Shop kaufen, das originale RTI-111 --Nicht für den menschlichen Konsum bestimmt! Von TEENn fernhalten. WIN-35428 und RTI-111 bestellt, RTI ist aber nie angekommen.. Mit Nachname. Vielen lieben Dank: fastlane [30.05.2017] Charge: 13.02.2017 Bewertung: In contrast to the closely related RTI-112, dichloropane is a potent stimulant drug which produces similar effects to cocaine as well as being structurally similar to.
    [Show full text]